

SUBJECT INDEX

- Accelerating rate calorimeter (ARC):
 nitro compound evaluation, 72–74
 process safety and, 67–68
- O-Acetyl-L-threonine, 218–219
- Acid scavengers, ionic liquids and, 350–351
- Acrylonitrile, electrochemical
 hydrodimerization, 368
- Active pharmaceutical ingredients (APIs):
 assay and stability, 120–122
 bureaucracy reduction and, 327–332
 chemical development objectives
 concerning, 53–56
 chemical process development and, 3–4
- Chemistry, Manufacturing, and Controls
 (CMC) document requirements,
 131–133
- controlled environment for manufacture,
 186–190
- crystal form and particle size, 119–120
- crystallization process, 124–126,
 177–181
- development report requirements,
 133–135
- dilevalol hydrochloride case study,
 268–294
- Good Manufacturing Practices and,
 110–113
- last process steps for, 122–126
- organic process waste disposal, 100–103
- outsourcing trends in, 335–337
- particle size engineering, 190–195
- patent considerations, 141–142
- pilot plant production of, 186–190
- quality control system for, 113–114
- quality specification and last process
 steps, 115–126
- regulatory issues, 109–113
- scale-up process, 167–169
- structure selection, 116–118
- sustainable discovery and development,
 377–380
- synthesis process selection, 13–14,
 127–131, 268–294
- technology transfer and, 135–137
- therapeutic team development of,
 51–53

402 SUBJECT INDEX

- Active pharmaceutical (*cont.*)
toxicology batch, 114–115
validation process, 133, 137–139
wastewater treatment, 103–107
workplace safety practices and, 84–86
- ACV tripeptide, cephalosporin C
fermentation, 204–208
- Adaptation, leadership skills and, 6–8
- Addiction chemistry, future trends in,
381–387
- Administrative procedures and SOP
manuals, 60
- Absorption, Distribution, Metabolism, and
Excretion (ADME) studies, 54,
116–118
- Adverse drug events (ADEs), regulatory
consequences, 111–113, 378
- Agenda, for internal symposia, 58–61
- Agitation equipment, 171
- Air pollution, process emissions, 89, 92–96
- Albuterol manufacture, process emissions
control and, 30, 93–96
- Alkaloids:
fantasy, 382–387
opiates poppy, 383–387
steroidal, 228
- Alkylation, microwave-assisted, 361
- Amikacin case study, patent protection and,
150–152
- 7-Amino-3-acetoxymethylceph-3-em-4-
carboxylate (7-ACA), 13, 19, 220,
267–268
patent protection in production of, 145–146
- 5-Aminoimidazole-4-carboxamide (AIC)
intermediate for temozolomide
manufacture, 295, 298–312
dihydrohypoxanthine hydrolysis,
311–312
preparation from hypoxanthine, 299–307
hypoxanthine reduction, 307–311
- 7(*R*)-Amino-3-methylceph-3-em-4-
carboxylic acid
(7-ADCA):
polymer synthesis, 353–355
quality control issues, 214–215
ring expansion research, 208–214
- 6-Aminopenicillanic acid (6-APA):
patent protection in production of,
145–146
penem synthesis and, 216–217
process patent case study involving,
152–155
quality control issues, 214–215
- 5-Amino-1 β -D-ribofuranosylimidazole-4-
carboxamide-5'-phosphate
(AICAR), 299
- Amorphous compounds, stability of,
119–120
- Amoxicillin development, 14
process patents and, 152–154
- Anabolic steroids, underground design of,
249
- Analytical Research and Development
organization, 57
- Androgens, natural sources, 229
- Antibiotics, treatment in wastewater,
106–107
- Anti-inflammatories commercialisation of,
240–249
- API-hydrochloride (API-HCl),
crystallization process, 178–181
- “Applied common sense” principles,
Standard Operating Procedures and,
63
- Arapahoe Chemicals, visionaries and
operating philosophy, 9–11
- Artemisinin, preparation of, 341–343
- Aspergillus* family, dilevalol hydrochloride
case study, 293–294
- Assays for quality control, active
pharmaceutical ingredients,
120–122
- Audit of facilities, preparing for a
pre-approval inspection, 138–139
- Auxoploes and auxochromes, 69–70
- Awards:
purpose and guidelines for, 32
safety award programs, 86
- Bank security system, patent for, 164
- Barbasco roots, status as a raw material
source, 258–260
- Batrachotoxin A, toxicity of, 228
- Beckmann rearrangement, oral
contraceptive production,
236
- Beecham Amoxicillin process, patents case
study and, 152–154

- Behavior-based safety programs,
characteristics of, 83–84
- Benzophenone hydrazone, electrochemical
oxidation, 373–374
- Betamethasone:
preparation of the alcohol, 260–264
intermediates and synthesis approaches
to, 255–264
- Betnovate, structure identification, 249
- Bile acids:
cholesterol degradation, 230–231
cortisone manufacture, 240–241
- Bill of Rights, 326
- Biological oxygen demand (BOD):
Clean Water Act provisions, 89
waste management, 199–200
wastewater treatment and, 103–107
- Bioluminescence process, patents
involving, 162–163
- Bioremediation techniques, wastewater
treatment, 105
- Biotechnology Department, chemical
process development and, 57
- Biotowers, wastewater treatment using, 105
- Biotransformation department:
purpose of, 58
ring expansion research and, 213
- Bisesterification, microwave-assisted
chemistry, 361
- Boron intermediates, patent issues
surrounding, 147–150
- Brain chemistry, a fantasy, 381–387
- Bristol-Myers:
cephalosporin research and, 12–14
patents case study and, 152–154
scientists and engineers in, 18–20
- N*-Bromoamides, 10
- Buchi-type filters, utility of, 181–182
- Bureaucracy, chemical process development
and reduction of, 326–332
- Business Development organization,
involvement of, 53
- n*-Butanol in dilevalol racemization and
recycle, 285
- Calorimeters, description of types, 67–69
- Capitalist economy, enhancing education in,
319–325
- Carbon dioxide, supercritical, 345–347
- Carbon oxygen demand (COD):
Clean Water Act provisions, 89
waste management, 199–200
wastewater treatment and, 103–107
- Carboxyl protecting groups:
patent protection issues and, 145–146,
154–155
ring expansion and, 209–213
- Catalytic hydrogenation, hypoxanthine
reduction to dihydrohypoxanthine,
308–311
in (S)-Metolacloclor manufacture, 339–340
- Catalytic oxidation, process emissions
control, 93
- Cefaclor:
manufacturing process for, 225–226
- Cefadroxil, 214
- Ceforanide, 215
- Cefotaxime, 215
- Ceftibuten dihydrate, licensing and
development, 220–226
- Ceftriaxone, 215
- Cefuroxime axetil, 215
- Center for Disease Control and Prevention
(CDC), 65–66
- Centrifugal pumps, 195
- Centrifugation:
basic equipment, 181–183
vapor explosions and, 81–82
- Cephalexin:
active pharmaceutical ingredient
competing processes, 11–12
patent infringement issues, 154–155
polymer-supported synthesis, 353–356
quality control issues, 214–215
ring expansion research and, 210–214
- Cephalosporins:
cephalosporin C fermentation, 204–208
development of, 204–226
classical cephalosporins, 220–226
penem synthesis, 215–220
penicillin G/cephalosporin C
fermentation, 204–208
penicillin sulfoxide-cephalosporin ring
expansion, 208–211
semisynthetic compounds, product
quality, 214–215
electrochemistry and, 220–226,
369–374

404 SUBJECT INDEX

- Cephalosporins: (*cont.*)
 esterification, 12, 118, 145–146, 152, 154, 209–212, 222–225, 348, 361, 369
 extraction process, 171–174
 extractive esterification, 212, 369
 penicillin sulfoxide ring expansion:
 patent issue, 154–155
- Cephapirin, 215
- Cephadrine, patent infringement by, 144–145
- Chemical engineering:
 agitation, 171
 computer applications, 200–201
 crystallization, working example, 177–181
 distillation/evaporation, 174–177
 education in, 321–325
 extraction, 171–174
 filtration, washing, and drying, 181–190
 flow measurement, 196–198
 heat exchange, 169–171
 overview stages of process development, 165–167
 pilot plant and plant maintenance, 201–202
 particle size reduction, 190–195
 process containment, 186–189, 282–284
 process scale-up, 167–169
 pumping systems, 195–196
 reactor volume measurement, 198–199
 waste management systems, 199–200
- Chemical Engineering for Chemists*, 165
- Chemical explosion, chemical structure classification, 69–70
- Chemical libraries, polymer-supported reagents, 357–358
- Chemical process development:
 bureaucracy reduction and, 326–332
 computer technology and, 200–201
 current Good Manufacturing Practices for, 113–139
 dilevalol hydrochloride case study, 268–295
 education and, 318–325
 evolution of, 166–167
 fantasy on brain chemistry, 380–387
 Florfenicol case study, 155–162
 mission and structure, 53–62
 objectives, 53–56
 organization, problems, needs, structure, functions and development, 49–63
 overview, 1–4
 patent protection and content, 141–143
 public image of, 50–51
 sustainable chemistry and evolution towards, 377–380
 synthesis methodology for, 127–131
 therapeutic teams for, 51–53
 water and enzymes, 337–344
- Chemical Safety and Hazard Investigation Board (CSB), mission and duties, 66
- Chemical safety organization, workplace safety practices, 82–86
- Chemicals handling, 96–103
- Chemistry, Manufacturing, and Controls (CMC) document:
 bureaucracy reduction and, 327–332
 FDA requirement for, 131–133
- Chiral hydroxylation, safety issues with an oxaziridine reagent, 75–76
- Chloramphenicol stearate,
 amorphous and crystalline forms of, 119–120
- Chloroform, contaminant and carcinogenic properties of, 217
- Cholesterol, biosynthesis, 230–231
- Cholesterol absorption inhibitors (CAIs), 226–227
- Cholic acid, progesterone from, 231
- Chromatographic purification, proposal of a process for bureaucracy reduction, 329–332
- Chromophores and phosphores, 69–70
- Clean Air Act (CAA):
 provisions of, 89–90
- Clean Water Act (CWA), provisions of, 89
- Cleavage reactions, polymer synthesis, 354–357
- Clogging problems in micromise operation, 192–195
- Collaboration, leadership and role of, 7–9
- Commitment, leadership skills and role of, 8
- Communication:
 leadership and role of, 7–9
 organizational structure and, 58–60, 63
- Competition, patent protection and, 145–155

- Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), overview of, 88
- Computer technology:
chemical process development, 200–201
maintenance programs and, 201–202
- Condition-based maintenance (CBM), principles of, 201–202
- Confetti patent, 162
- Containment of processes, 186–189
- Continuous-flow reactors, 171–173, 350–351, 359–366
- Contraceptives, production of, 235–240
- Controlled environment rooms (CERs), requirements in, 186–190
- Convergent synthesis, last process steps for APIs, 122–124
- Coriolis mass flowmeters, flow measurement, 196–198
- Cortisone, early research and improved anti-inflammatories, 230, 240–249
- Corynebacteria*, cortisone research and improved anti-inflammatories 242–249
- Cost-of-goods (COG) projections:
dilevalol hydrochloride case study, 269–272, 275–279
process development and alternative routes, 290–294
electrochemistry and, 220–225, 366–372
patent issues and, 146–150
- Cross contamination, 21–22, 217
- Crotonylation reaction, albuterol process with lower emissions, 95–96
- Crystalline structures effect on active pharmaceutical ingredients, 119–120
- Crystallization, basic principles of, 177–181
- Cucurbitacins, medicinal properties, 227–228
- Current Good Manufacturing Practice (cGMP):
bureaucracy reduction and, 327–332
chemical process development, 113–139
evolution of, 110–113
- Cyanoacetamide,
5-aminoimidazole-4-carboxamide (AIC) preparation, 298
- Dacarbazine (DTIC), 296
- D-amino acid oxidase (DAAO),
cephalosporin research and, 12–13, 206–208, 220
- DAST reagent, Florfenicol development and, 157
- DBTA salt formation:
dilevalol development and, 273–290
n-butanol racemization and recycling, 285
- Deacetoxycephalosporin C synthase (DAOCS), ring expansion process, 213–214
- Deacetoxycephalosporin G (DAOG), ring expansion of penicillin G to, 213
- 10-Deacetylbaccatin III, raw material for taxol, 342–343
- Dehydration reactions, steroid chemistry, 260–264
- Dehydrogenation at C-1,2 to enhance anti-inflammatory activity, 242–247
- Delegation, as leadership skill, 6, 9
- Desogestrel, synthesis of, 237, 239–240
- Desoxymethyltestosterone, underground production of, 251
- Developing countries, outsourcing drug development to, 335–337
- Development organization, structure and function, 56–61
- Development reports:
components of, 133–135
pre-approval inspection and, 133
- Dialogue, leadership and promotion of, 7–9, 58–60
- Diazomethane, 16 β -methyl intermediates and, 252–260
- Diels-Alder reaction:
electrochemistry and, 368
microwave-assisted chemistry, 360
water promoted, 338
- Differential scanning calorimetry (DSC):
assessment of explosion potential, 70–72
process safety and, 67
- Digoxin, medicinal use of, 228–229
- Dihydrohypoxanthine:
hydrolysis to AIC, 311–312
hypoxanthine reduction to, 307–311

406 SUBJECT INDEX

- Dilevalol hydrochloride:
 cardiovascular therapy applications, 269, 294
 commercial process case study, 268–294
 DBTA salt conversion to, 285–287
 overview, 269–272
 n-butanol racemization and recycling, 285
 NDA process to commercial scale development, 275–290
 ongoing process development and alternative routes, 290–294
 process engineering for, 281–290
 synthesis route research, 271–272
 withdrawal from market, 294
- Dimethyl-POPOP, development of, 10
- Diosgenin:
 norethindrone production from, 236
 isolation of, 232
 16 β -methyl intermediates and, 252–255
- Diphenyldiazomethane (DDM):
 electrochemical route, 373–374
 polymer supported, 353–356
 ring expansion research and, 210–212
- Diphenylmethyl (DPM) group:
 cephalexin development and, 12
 patent issues involving, 154–155
 polymer synthesis, 353–358
 ring expansion research and, 210–212
- Dissolution rate, API-hypochloride crystallization and, 179–181
- Distillation, Evaporation, 174–177
- Documentation SOP's:
 governing controlled environment rooms, 186
 governing analytical instruments, 138
 governing pilot plants, 60–61
 governing process safety, 84–86
 governing technology transfer, 136
 last process steps for APIs and, 126
- Doppler effect, flow measurement, 197
- Drug discovery:
 organizational structure matrix, 52–53
 patent protection and, 141–142
- Drug Master File (DMF):
 Chemistry, Manufacturing, and Controls (CMC) document requirements, 126, 132–133
 IND/NDA applications, 126
- Dryer systems:
 basic equipment, 184–190
 micronization consideration, 192–194
- Drying times, API-hypochloride crystallization and, 178–181
- Dust explosions, safety procedures for, 80–81
- Education:
 chemical process development and, 318–325
 sustainable development and, 376–377
 synthesis technologies and, 333–335
- Electrochemistry:
 redox reactions using, 366–374
 use in wastewater treatment, 106–107
- Electrodialysis, wastewater treatment using, 106–107
- Electrospray-mass spectroscopy, microwave-assisted hydrolysis of dihydrohypoxanthine, 365–366
- Embrittlement of solids, particle size reduction and, 194–195
- Emergency Planning and Community Right-to-Know Act (EPCRA):
 chemicals handling formalization, 97–100
 provisions of, 90
- Enantiomer structure, dilevalol hydrochloride research and, 269–270
 DBTA salt formation, 283–284
- Enantioselective processes, water and enzyme chemistry and, 339–344
- Environmental issues:
 cephalosporin C development and, 208
 chemicals handling procedures, 96–100
 organic process wastes, 100–103
 overview of, 87–88
 practical operations and, 91–107
 regulatory acts concerning, 88–91
- Environmental Protection Agency (EPA):
 interaction with safety agencies, 66
 wastewater treatment initiatives, 106–107
 workplace safety practices and, 84–86
- Environmental scientists, within the chemical development organisation, 57

- Enzymes:
in chemical process development, 12–13,
206–208, 220, 290, 292–293,
337–344
microwave-assisted chemistry and,
363–364
- Eosinophilia-myalgia syndrome (EMS),
111–112
- Ergosterol, conversion to Dihydroergosterol,
234
- Esterification:
anti-inflammatory research, 243–248
cephalosporins, 12, 118, 145–146, 152,
154, 209–212, 224–225, 348, 361,
369
microwave-assisted chemistry, 361–369
- Estrogens, identification of, 229
- Estrone, production of, 236
- European Inventory of Existing Chemical
Substances (EINECS), 91
- European List of Notified Chemical
Substances (ELINCS), 91
- Evaporation, Distillation, 174–177
- Exotherm reactions,
methyl(S)-phenylglycinate
hydrochloride (POX-C) reduction,
78–80
- Explosions:
centrifugation and, 182
chemical explosion, 69–70
differential scanning calorimetry
analysis, 70–72
dust explosion, 80–81
vapor explosion, 81–82
- Extraction:
basic equipment, 171–174
extractive esterification, 212, 224–225
- Extremely hazardous substances (EHSs),
classification of, 97–100
- Ezetimibe:
Schering-Plough synthesis for, 226–227
synthesis methodology for, 127
- Failure, leadership skills in dealing with, 7
- Felbamate, patent lessons, 146–150
- Fermentation of penicillin G and
cephalosporin C, 204–208
- Filtration:
basic equipment for, 181–190
- Fischer indole synthesis,
microwave-assisted chemistry,
360–361
- Flammable solvents, management of,
81–82
- Flexibility, leadership and role of, 6–8
- Florfenicol development:
patent aspects of, 155–162
process improvements for, 160–162
synthesis methodology for, 128
- Flow measurement, instruments for,
196–199
- Fluid bed dryers, 186
- Flutamide, 117, 379
- Fluorination reactions:
anti-inflammatory research and, 243–248
Florfenicol development and, 156–160
reactive system screening tool, 74–75
- Food, Drug and Cosmetic Act, 110
- Food and Drug Administration (FDA):
API-hydrochloride crystallization and,
178–181
approval process for, 314
bureaucracy reduction and, 329–332
chemical process development and, 2–4
dilevalol hydrochloride case study,
280–290
chemistry, manufacturing, and controls
document requirements, 131–133
Compliance branch activities, 138–139
dilevalol hydrochloride review, 288–290
regulatory history of, 110–113
Review Branch requirements, 131–133
sustainable chemistry and, 378–380
validation process and, 138–139
workplace safety practices and, 84–86
- Forced-air-heated dryers, environmental
requirements, 184–185
- Friedel-Crafts reaction, polymer-supported
synthesis, 353–357
- Fugitive emissions, 92
- General Agreement on Trades and Tariffs
(GATT) treaty, 142
- Generally Regarded as Safe (GRAS)
solvents, particle size reduction case
study, 192–195
- Gestagens, identification of, 229
- Gettysburg address, 326

408 SUBJECT INDEX

- Glaxo Laboratories:
antibiotics chemistry at, 11–14
cortisone and improved
anti-inflammatories, 234–248
patent protection issues and, 145–146,
154–155
scientists and engineers in, 17–18
7-Glutaroylamino-3-acetoxymethylceph-3-
em-4-carboxylic acid (II),
electrochemical reduction, 222–225
Good Manufacturing Practice (GMP):
evolution of, 110–113
maintenance practices, 201–202
Government inspections, organic process
waste disposal and, 102–103
Green chemistry:
organic process waste disposal and,
101–103
supercritical fluids and, 346–347
using water/enzyme systems, 337–344
Grignard reagents:
development of, 9–10
16 β -methyl intermediates and, 253–255
Hazard and Operability Study (HAZOP),
runaway reactions, reactive system
screening tool, 74–76
Hazardous waste management, and
environmental laws, 88–91
Headcount, for Safety groups, 57–59
Heat exchange and control of, 169–171
Hecogenin:
raw material for anti-inflammatory
steroids, 234, 258
plant sources of, 258–260
Heinkel-type centrifuge, 183–184
Heptane, flammability characteristics,
81–82
Homogeneous energy supply,
microwave-assisted chemistry,
358–359
Horizontal spindle centrifuge, properties of,
183–184
Human resources, organization and function
of, 61–62
Hydrocortisone, structural foundation for
commercial anti-inflammatories,
242–248
Hydrolysis:
AIC chemistry, 306–307
dihydrohypoxanthine to AIC, 311–312
Florfenicol development and, 161–162
9 α -Hydroxyandrost-4-ene-3,17-dione, raw
material for steroids, 255–257
p-Hydroxybenzaldehyde, 368–374
11 α -Hydroxylated betamethasone
intermediate, dehydration to C-9,
11-dehydrate steroid, 260–264
Hypoxanthine, 5-aminoimidazole-
4-carboxamide from, 299–307
dihydrohypoxanthine from, 307–311
Ignition, vapor explosions, 81–82
Impact sensitivity test, Nitro-dur scrubber
charcoal, 70–73
Impurities assay:
active pharmaceutical ingredients,
120–122
patent process and, 151–152
Incineration:
organic process waste disposal, 100–103
process emissions control and albuterol
case study, 93–96
Indefinite drug development program,
53–54
Industrial organization, some issues, 49–51
Industrial waste, government classification
of, 102–103
INOX-GLATT dryer, particle size and
milling issues, 192–195
Intermediate chemicals analysis group,
development of, 28, 57, 59
Internal symposia, importance of, 58–61
International Conference on Harmonization
(ICH), solvent guidelines from,
124–126
International Organization for
Standardization:
environmental standard (ISO 14000), 91
quality assurance standards (ISO 9000),
129–130
Investigational New Drug (IND) process:
API assay, impurities assay, and product
stability, 120–122
bureaucracy reduction and, 327–332
dilevalol hydrochloride case study,
268–294
filing procedures, 126

- regulatory guidelines for, 112–113
synthesis methodology and, 130–131
toxicology batch, 114
- Ion exchange, extraction process and, 173–174
- Ionic liquids, properties and uses, 348–351
- Iron contaminants, radex safety calorimeter test, 76–78
- Ishikawa reagent, runaway reactions, reactive system screening tool test, 74–76
- JANAF drop weight test, explosives analysis, 70–73
- Jet pulverizer micronizer, particle size reduction, 192–195
- Karr column, extraction using, 172
- Keto aldehyde hydrate (KAH), process emissions control, 93–96
- Kraus-Maffei process containment unit, 187–189, 282–284
- Labetalol:
cardiovascular, properties vs. those of dilevalol, 269–270
dilevalol hydrochloride separation from labetalol vs. synthesis, 270–272
- Labile reagent stability, radex safety calorimeter evaluation, 76–78
- β -Lactams:
future prospects, 226–227
microwave-assisted chemistry and, 363
overview, 203–204
penicillins and cephalosporins, 204–226
classical cephalosporins, 220–226
penem synthesis, 215–220
penicillin G/cephalosporin C fermentation, 204–208
penicillin sulfoxide-cephalosporin ring expansion, 208–211
semisynthetic compounds, product quality, 214–215
- Lagoons, wastewater treatment using, 105–107
- Last process steps:
active pharmaceutical ingredients, 122–126
technology transfer and, 135–137
- Late-stage intermediates, defining the synthesis methodology, 127–131
- Lawesson's reagent:
cephalosporin development, 225–226
quazepam manufacture, 30
- Leadership:
attributes of, 6–9
chemical process development and role of, 5–9
role in organization of, 62–63
specifications and criteria for, 8–9
- Lethal and toxic chemicals, extremely hazardous substances classification, 96–100
- Liquid-liquid extraction, 171–174
- Liquid sulfur dioxide, properties and potential, 347–348
- Listening skills, leadership and role of, 7–9
- Loratidine, 117, 379
- Lovastatin, 342
- Lumisterol, steroid raw material, 234
- Magnetic flowmeters, flow measurement, 196–197
- Maintenance procedures, pilot plants, 201–202
- Management, internal symposia and role of, 58–60
- Management:
disciplines managed by chemical process development, 1–4
agreement an organisational structure, 14–15, 57–58
- Manufacturing:
chemical process bridge to, 55–56
internal symposia and content of, 57–61
- Marker degradation process, 232–233, 236, 258, 373
- Marketing organization, place in drug discovery, 53
- Masked methyl isocyanates, temozolomide preparation, 312
- Mass spectrometry:
analytical involvement in AIC project, 298
AIC chemistry, 300–307, 310–312

410 SUBJECT INDEX

- Mass spectrometry: (*cont.*)
 hypoxanthine reduction to
 dihydrohypoxanthine, 308–311
- Material Safety Data Sheets (MSDS):
 contents of, 85
 extremely hazardous substances
 classification, 97–100
 introduction to Safety/Health, 66
 workplace safety practices and, 84–86
- Matrix organization, drug discovery and
 development, 51–53
- Media, pharmaceutical industry coverage
 by, 50–51
- Medical organization in drug discovery and
 development, 52–53
- Mercury cathodes, replacement in
 electrochemical cells, 222–224, 372
- Mestranol/norethinodrel compound,
 233–235
- Metabolite development, API structure for,
 116–118, 379
- Metastable intermediates, chemical
 explosion, 69–70
- Method stage, chemical process
 development and, 3–4, 165–167
- 16 β -Methyl intermediates and, saponins to,
 252–260
- Methyl formate process to Felbamate
 intermediate, patent issues and,
 146–150
- Methylhydrazine, temozolomide
 preparation, 313
- Methyl isobutyl ketone (MIBK), DBTA salt
 to dilevalol hydrochloride, 285–289
- Methyl (6S, 7R, 8R) 6-1(1-
 trichloroethoxycarbonyloxyethyl)
 penicillanate, 216–217
- Methyl salicylate, raw material for albuterol
 synthesis, 93–96
- Methyl(S)-phenylglycinate hydrochloride
 (POX-C), reduction, use of RC-1 for
 heat of reaction study, 78–80
- Methyl tropate reduction, for Felbamate
 intermediate, patent issues
 surrounding, 146–150
- Metolaclor manufacture, 339–340
 supercritical fluids and, 346–347
- Mettler RC-1 calorimeter, 68–69
- Microbial contaminant counts, quality
 control assays, 120
- Micronization:
 overcoming clogging problems during,
 192–194
 particle size reduction, 190–195
 progesterone, 235
 unit designs, 191, 192
- Microorganism, organic process waste
 disposal and, 103–106
- Microwave-assisted chemistry, trends and
 technologies, 358–366
- Milling process, particle size reduction,
 190–195
- Mitozolomide, 296
- Mitsubishi Rayon acrylamide process,
 340–341
- Molecular foundations and designing round
 process patents:
 amoxicillin, 152–153
 cephalosporin, 154–155
- Molecular foundations of the steroid
 industry, 227–229
- Mometasone Furoate and raw material
 selection, 256–257
- Monsanto process, electrochemical
 dimerisation of acrylonitrile, 368
- Morphinans, biosynthesis inhibition,
 385–387
- National Academy of Sciences, 321
- National Institute of Safety and Health
 (NIOSH), mission, 65
- National Research and Development
 Council (NRDC), licensing process,
 209–210
- National Research Council (NRC),
 cortisone program of, 240
- New Drug Applications (NDA):
 API-hypochloride crystallization and,
 178–181
 bureaucracy reduction and, 327–332
 Chemistry, Manufacturing, and Controls
 (CMC) document requirements,
 131–133
 dilevalol hydrochloride case study,
 268–294
 FDA review and compliance, 288–290
 filing documentation, 126
 quality control, impurities and stability,
 121–122
 regulatory guidelines for, 112–113

- synthesis methodology and, 130–131
- validation process, 133, 137–139
- Nitric acid oxidation, recycling benzhydrol waste, 211–214
- Nitro-dur scrubber charcoal, differential scanning calorimetry analysis, 70–72
- Nitronates, accelerating rate calorimetry analysis, 72–74
- p*-Nitrophenyl chloroformate, temozolomide preparation, 313
- Norethindrone, Syntex process for, 235–236
- Norgestrel, synthesis of, 237–240
- Notification of New Substances (NONS), extremely hazardous substances classification, 97–100
- Nutrex unit, components of, 188–190
- Occupational Safety and Health Administration (OSHA):
 - carcinogenic chemicals list, 97
 - mission and activities, 65–66
 - process emissions protection, 93
 - workplace safety practices, 82–86
- Olefin byproducts, steroid chemistry, 260–264
- Operating structure, organization of, 58–61
- Operational procedures, standard operating procedures, 60–61
- Oral contraceptives, early research on, 231–234
- Orally absorbed antibiotics, ring expansion and, 209
- Organic chemical synthesis trends:
 - electrochemistry, 367–341
 - microwave-assisted chemistry and, 358–366
 - outsourcing, 335–337
 - other “solvents,” 344–351
 - use of polymer supports, 351–358
 - water and enzymes and, 337–344
- Organic Process Research and Development* (journal), 164
- Organic process wastes, management of, 100–103
- Organization:
 - in chemical development, 56–61
 - development through, 61–62
 - leadership role in, 6–9
 - mission and structure, 53–56
 - promotions in, 34–35
 - structure and function, 49–51, 59
 - therapeutic teams, 51–53
- Orifice/Venturi meters, flow measurement with, 196–197
- Oseltamivir (Tamiflu), preparation of, 341–343
- Outsourcing:
 - current trends in, 314, 335–337
 - last process steps for APIs and, 123–126
- Oxaziridine stability, radex safety calorimeter test, 76–77
- Oxygen sensors, centrifuge explosion and, 182
- Ozonolysis:
 - cephalosporin synthesis and, 221–225
 - clean albuterol synthesis, 94–96
- Papaverine, biosynthesis of, 385–386
- Particle size:
 - active pharmaceutical ingredients, 119–120
 - milling, micronization, and precipitation processes, 190–195
 - progesterone, 235
- Patents:
 - application content and process, 142–143
 - chemical process development and, 56–58
 - defense procedures for protection of, 150–152
 - history and exclusivity, 141–142
 - motivations for seeking, 143–144
 - odd patents, 162–164
 - timeliness of, 145–150
 - trade secrets vs., 155
 - worth of, 144–145
- Penicillins, development of, 204–226
 - classical cephalosporins, 222–226
 - penem synthesis, 215–220
 - penicillin G/cephalosporin C fermentation, 204–208
 - penicillin sulfoxide-cephalosporin ring expansion, 208–211
 - semisynthetic compounds, product quality, 214–215
- Penems’
 - synthesis of, 215–220
- Penicillins:
 - extraction equipment, 172–173

412 SUBJECT INDEX

- Penicillins: (*cont.*)
penicillin G development, 204–206,
208–214
6-APA quality problem, 214
Penicillin sulfoxides, ring transformation to
cephalosporins:
patent case, 154–155
process for, 208–214
People, vital importance of, 5–47
Perry's Chemical Engineers Handbook,
165–166
Pharmaceutical Development scientists,
API collaboration with, 117–118,
177–181, 190–194
Pharmaceutical industry:
future trends in, 381–387
organizational structure in, 50–51
sustainable innovation, 327–332,
377–380
Pharmaceutical Research and
Manufacturers Association
(PhRMA):
organizational structure, 50–51
quality control and regulatory issues,
140
1-Phenyl-1,3-propanediol (PPD), felbamate
patent issues and, 146–150
Phosphorus compounds, steroid chemistry
and, 261–264
Phosphorus trichloride cleavage process,
patent protection for, 145–146
Pilot plants:
controlled environment rooms,
186–190
maintenance of, 201–202
multipurpose reactor package, 169–170
Piston pumps, 195–196
Plant-based chemistry:
future trends in, 105, 341–342, 381–387
steroids and, 256–260
Plant equipment and maintenance,
technology transfer and, 136–137
Plant failure analysis, runaway reactions,
reactive system screening tool,
74–76
Phosphore and chromophore, 69–70
p-Nitrobenzyl (PNB) protecting group:
cephalexin development and, 11–12
patent issues involving, 154–155
ring expansion research and, 209–211
Polychlorinated biphenyls (PCBs), Toxic
Substances Control Act provisions
concerning, 90
Polymers:
microwave-assisted chemistry and,
362–366
reagents, 357–358
synthesis methods and, 351–358
Positive displacement pumps, basic
principles, 195–196
Post-emissions calculations, air pollution
from process emissions, 92–93
Practical operations, environmental issues
in, 91–107
Pre-approval inspection (PAI):
development report, technology, transfer,
and validation, 133
dilevalol hydrochloride case study, 109,
289
new drug development and, 112–113,
133–139
Precipitation, particle size reduction,
190–195
Predictive maintenance, 201
Prednisolone, and improved
antiinflammatories, 242–249
Prednisone, and improved
antiinflammatories, 242–249
Pregnanediol issues, 231
Pressure issues, microwave-assisted
chemistry, 358–359
Preventive maintenance, 201–202
Process changes, technology transfer and,
136–137
Process development phase:
chemical process development and, 3–4,
165–167
computer technology and, 200–201
Process emissions:
to the air, 92
organic process waste, 100
wastewater, 103
Process engineering, dilevalol
hydrochloride case study,
282–289
Process hydration, opportunities, 102,
343–344
Process patents:
designing around patents, 152–155
process protection, 150–152

- Process productivity, improving
 electrochemistry, 372
- Process safety:
 calorimetric equipment for, 67–69
 chemical structure with explosion risk,
 69–70
 chemical process development and, 2–4
 runaway reactions, 74–76
 overview of, 65–86
 systems for, 57–61
 workplace safety practices, 82–86
- Process wastes, early management of, 92
- Pro-drug development, active
 pharmaceutical ingredients and,
 116–117
- Product stability assessment, active
 pharmaceutical ingredients,
 116–117
- Progesterone:
 natural sources, 229–235
 oral contraceptives based upon, 235–240
- Progestogens, sources of, 233–237
- Promotion system, chemical process
 development and, 34–35
- Pteris vittata*, wastewater treatment using,
 105
- Publicly owned treatment works (POTW):
 Clean Water Act provisions, 89
 process emissions and, 92
 wastewater treatment, 103
- Pumping techniques and pump capabilities,
 195–196
- Purchasing chemicals and restrictions on,
 97–99
- Quality control (QC):
 active pharmaceutical ingredients, 57, 59
 API assay, impurities assay, and product
 stability, 120–122
 API quality specification and last process
 steps, 115–116
 API structure for, 116–118
 chemical process development system
 for, 113–114
 crystal form and particle size, 119–120
- Development report and, 133–135
 dilevalol hydrochloride case study, 275,
 279–280
 electrochemical route to cephalosporins,
 220, 225, 372
 last process step guidelines, 122–126
 semisynthetic penicillins and
 cephalosporins, 214–215
 synthesis methodology research and,
 129–132
- Radar detectors, reactor volume
 measurement, 199
- Radex safety calorimeter:
 iron contaminants, labile reagent
 stability, 76–78
 process safety and, 68
- R-aminoketone enzyme reduction, dilevalol
 hydrochloride case study,
 293–294
- Reaction calorimeter (RC1):
 optimisation of
 methyl(S)-phenylglycinate
 reduction, 78–80
 process safety and, 68–69
- Reaction temperature enhancement using
 microwave-assisted chemistry,
 359–366
- Reaction vessels, chemical engineering
 perspective on scale-up,
 167–169
- Reactive system screening tool (RSST):
 process safety and, 68
 runaway reactions analysis, 74–76
- Reactor jackets, pilot plant reactors,
 170–171
- Reactor volume measurement,
 198–199
- Reagents:
 electricity, 367–374
 enzymes, 337–344
 polymer-supported, 357–358
- Receiving company (RC), outsourcing,
 335–337
- Recipe stage, chemical process
 development and, 3–4, 113,
 166–167
- Recrystallization, Florfenicol development
 and, 160–161
- Registration, Evaluation and Authorization
 of Chemicals (REACH) program,
 97–100
- Regulatory Affairs department,
 supplementary reinforcement of,
 57–58

414 SUBJECT INDEX

- Regulatory issues:
 bureaucracy reduction and, 326–332
 overview of, 109–113
 sustainable chemistry, 377–380
- Research and development matrix
 organization, characteristics of,
 51–53, 62–63
- Research organizational structure,
 therapeutic team composition,
 51–53
- Residue-on-ignition (ROI) content, quality
 control assays, 120–122
- Resins, extraction process and, 173–174
- Resource availability, utilization vs.,
 52–53
- Resource Conservation and Recovery Act
 (RCRA):
 description of, 88–89
 extremely hazardous substances
 classification, 97–100
- Reticuline in morphinon biosynthesis,
 385–387
- Reverse osmosis (RO), basic principles,
 177
- Rhizopus arrhizus*:
 progesterone hydroxylation, 240–241
- Ring expansion:
 penicillin sulfoxides to cephalosporins,
 208–211
 polymer synthesis, 353–357
- Risk Management Program (RMP),
 development of, 66
- R-1-methyl-3-phenylpropylamine, dilevalol
 hydrochloride and process for,
 277–279
- Rotameters, flow measurement with, 196
- Rotary pumps, basic principles, 195–196
- RR-amine process:
 dilevalol hydrochloride research,
 273–276
- R,R-Amine preparation, 273
- Runaway reactions:
 methyl(S)-phenylglycinate hydrochloride
 (POX-C) reduction, 78–80
 preparation of Ishikawa reagent, 74–76
- Safe Drinking Water Act (SDWA),
 provisions of, 90
- Safety and Environmental Departments:
 environmental regulations and the
 oversight of compliance, 87–108
 safety in chemical process development
 organisation, 57–61
 workplace safety practices, 82–86
- Safety award programs, workplace safety
 and, 86
- Salt formation:
 of active pharmaceutical ingredients,
 117–118
 API-hypochloride crystallization and,
 179–181
 dilevalol DBTA salt development,
 280–287
- Saponins, 16 β -methyl intermediates from,
 252–260
- Sarsasapogenin:
 intermediates research and, 255–260
 isolation of, 232, 257–260
- Scale-up:
 basic principles of, 167–169
 electrochemistry and, 370–372
- Schering penem Sch 29482, 218
- Schering penem Sch 34343, 216–220
- Schering-Plough Company:
 awards for, 32–34
 Ceftibuten development and, 220–227,
 369–373
 consultants with, 31–32
 Florfenicol development and, 155–162
 scientists and engineers at, 20–31
- Science education, future needs in,
 322–325
- Scientists and engineers, chemical process
 development and role of, 5, 15–47
- Scrubber charcoal, safety procedures for,
 70–72
- Scrubbing systems, process emissions
 control, 92–93, 183–185
- Shionogi synthesis process, Ceftibuten,
 220–226
- Sodium dispersion chemistry:
 development of, 10–11, 190–191
 particle size, 190–191
- Solvents:
 capture equipment for, 92–93, 183–185
 current research trends, 344–351
 distillation and evaporation, 174–177
 extraction process and, 172–174

- ionic liquids, 348–351
- last process steps for APIs and ranking of, 124–126
- liquid sulfur dioxide, 347–348
- microwave-assisted chemistry, 358–366
- organic process waste disposal and recycling of, 100–101
- recovery data for, 176–177
- supercritical fluids, 345–347
- Spherical dryers, 186
- Spray dryers, 186
- Standard Operating Procedures (SOPs):
 - controlled environment rooms, and, 186
 - chemicals handling process and, 99–100
 - maintenance practices, 201–202
 - organizational structure and, 60–61, 63
 - technology transfer, 136–137
 - workplace safety practices and, 84–86
- Steroids:
 - anti-inflammatories, 240–249
 - betamethasone intermediate-
 - betamethasone alcohol conversion, 260–264
 - contraceptive synthesis development, 235–240
 - cucurbitacin molecular structure, 227–228
 - early history, 227–235
 - future research possibilities, 265
 - last process steps in manufacturing of, 122
 - molecular structure, 249–252
 - saponin-16 β -methyl intermediates, 252–260
 - steroids with diverse biological activity, 249–251
 - structural chemistry, 227–235
- Stigmasterol, raw-material, 231
- Stirrer designs, sodium dispersion, 190–191
- Sulfoxide, electrochemical reduction of a cephalosporins, 224–226
- Supercritical fluids as solvents, 345–347
- Superfund Amendment and Reauthorization Act (SARA), outline of, 88
- Sustainable chemistry:
 - development of, 375–380
 - enzyme and fermentation processes, 101–103
- Syntex oral contraceptive process, 235–238
- Synthesis methodology:
 - electrochemical radar reactions, 366–375
 - microwave-assisted chemistry, 358–366
 - polymer-supported synthesis and reagents, 351–358
 - research and development considerations, 127–131
 - trends and technologies for, 333–334
 - water and enzyme chemistry and, 337–344
- Tank systems, wastewater treatment using, 105
- Target molecule, stages of process development, 166
- Technology transfer:
 - and development report of, 133
 - chemical development and, 56
 - internal symposia discussion of, 57–61
 - pre-approval inspection and, 133
 - SOP for, 135–137
- Temozolomide:
 - 5-aminoimidazole-4-carboxamide (AIC) chemistry, 298–312
 - dihydrohypoxanthine hydrolysis, 311–312
 - preparation from hypoxanthine, 299
 - hypoxanthine reduction to dihydrohypoxanthine, 307–311
 - original manufacturing process, 296–297
 - new preparation chemistry for, 312–313
- Tetrahydrogestrinone, 249
- Therapeutic teams, chemical development and, 51–53
- Thiamphenicol route to Florfenicol intermediate, 156–160
- Thin-film evaporation equipment, 176
- Thin-layer chromatography, in improved process to albuterol, 94–96
- Third party manufacturers:
 - Chemistry, Manufacturing, and Controls (CMC) document requirements, 131–132
 - initial process exploration with, 156–160
 - last process steps for APIs and, 123–126
 - patent agreements with, 155–156
 - qualifying a third party, 129–131
 - risks in outsourcing, 314, 335–337

416 SUBJECT INDEX

- Threshold limit values (TLVs), process emissions protection, 66–67, 93
- Tigogenin, plant sources of, 258–260
- Time-weighted averages (TWAs), process emissions protection, 66–67, 93
- Toxicology batch, 114–115
- Toxic Substances Control Act (TSCA):
extremely hazardous substances
classification, 97–100
provisions of, 90–91
- Trade secrets, patents vs., 155
- 2,2,2-Trichloroethyl (TCE) group:
process patent case study involving, 154–155
ring expansion and, 209–214
- Trifluoroacetic acid (TFA), solvent for indole hydrogenation, 308–311
- Trimethylsilyl (TMS) group, ring expansion research and, 212
- Trust, leadership and role of, 6
- Tryptophan, eosinophilia-myalgia syndrome and, 111–112
- Turbine pumps and flow measurement, 196
- Ultrasonic flowmeters, flow measurement with, 197
- Ultrasonic level measurement, principles of, 198–199
- Vacuum distillation, basic principles, 174–176
- Vacuum drying systems, properties of, 185
- Validation:
components of, 137–139
pre-approval inspection and, 133
- Vapor explosions, safety procedures for avoidance, 81–82
- Venturi feed mechanism in micronizer, clogging problems, 192–195
- Vinblastine analogues, 343
- Visionaries:
characteristics of, 9–15
chemical process development and role of, 5, 9–15
- Volatile organic compounds (VOCs):
in process emissions, 92–93
wastewater treatment and, 103
- Washing filter cakes efficiently, 181–183, 186
- Waste management requirements, 199–200
- Wastewater treatment, guidelines and issues, 103–107
- Water, solvent in chemical process development, 337–344
- Water-for-injection (WFI) system, quality control in chemical process and, 113
- Water/solvent content importance of in an API micronization study, 192–194
- Workplace environment:
importance of people, 5–6
safety practices in, 82–86
- Yucca brevifolia*, steroids from, 258
- Yucca filifera*, steroids from, 259
- Zambon, Florfenicol development and, 156–162